Hi,

I've been on androcur, estrogel & motillium for a couple months. The nuts are a little smaller and softer. Sex drive is gone. What else could I do to shrink the testicles? Any thoughts?

Dale

Hi,

dale (imported) wrote: Wed Aug 30, 2006 10:50 am I've been on androcur, estrogel & motillium for a couple months. The nuts are a little smaller and softer. Sex drive is gone. What else could I do to shrink the testicles? Any thoughts?

DaleIf you are on the correct dose then you are doing about all you can do.

Wish you luck.

When I was just on androcur my balls shrunk almost 50% in volume. I liked that very much. The shrinkage took time to happen. A few months is a very short time.

Put a little green band around them? Sorry, but what effect are those drugs having on you? Are you getting regular tests on your liver, etc? I have read that some people who have used them have had health related problems.

Here's something to consider:

Androcur - Androcur Side Effects

Contraindications: Known hypersensitivity to the drug. Active liver disease and hepatic dysfunction. Renal insufficiency.

Warnings: Liver Function: Direct hepatic toxicity, including jaundice, hepatitis and hepatic failure, which has been fatal in some cases, has been reported in patients treated with 200 to 300 mg cyproterone. Toxicity is dose-related and develops usually, several months after treatment has begun. Liver function tests should be performed before treatment and whenever any symptoms or signs suggestive of hepatotoxicity occur. If hepatotoxicity is confirmed, cyproterone should normally be withdrawn, unless the hepatotoxicity can be explained by another cause, e.g., metastatic disease, in which case cyproterone should be continued only if the perceived benefit outweighs the risk.

Inhibition of Spermatogenesis: The sperm count and the volume of ejaculate are reduced at oral doses of 50 to 300 mg/day. Infertility is usual, and there may be azoospermia after 8 weeks of therapy, which is associated with atrophy of seminiferous tubules.

Follow-up examinations on discontinuation of therapy have shown these changes to be reversible.

Spermatogenesis usually reverts to its previous level about 3 to 5 months after stopping cyproterone, or in some patients, after up to 20 months. Production of abnormal spermatozoa during cyproterone therapy has been observed; their relationship to abnormal fertilization or malformed embryos is not known.

Gynecomastia: Benign nodules (hyperplasia) of the breast have been reported, these generally subside 1 to 3 months after discontinuation of therapy and/or after a reduction of dosage. The reduction of dosage should be weighed against the risk of inadequate tumor control.

Depression: Cyproterone therapy has occasionally been associated with an increased incidence of depressive mood changes, especially during the first 6 to 8 weeks of therapy. Similar mood changes have also been seen following surgical castration and are considered to be due to androgen deprivation. Patients with tendencies to depressive reaction should be carefully observed.

Precautions: Thromboembolism: Clinical investigations have shown that when cyproterone is used alone it has a minor effect on blood clotting factors. However, when cyproterone was combined with ethinyl estradiol, changes were found in increased coagulation capability. There is an inherent risk for those patients with a history of thrombophlebitis or thromboembolism for recurrence of the disease. Cyproterone should be discontinued at the first sign of thrombophlebitis or thromboembolism, and the patient should be carefully re-evaluated if manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular complications, retinal thrombosis or pulmonary embolism) occur.

Adrenocortical Function: Suppression of adrenocortical function tests have occurred in patients receiving high doses (100 mg/m 2) of cyproterone.

Reduced response to endogenous ACTH was noted by metyrapone test; furthermore, reduced ACTH and cortisol blood levels determined by the Mattingly method were also found.

It is therefore recommended that adrenocortical function tests should be monitored periodically by serum cortisol assay.

Diabetes: Cyproterone may impair carbohydrate metabolism. Parameters of carbohydrate metabolism, fasting blood glucose and glucose tolerance test, should be examined carefully in all patients and particularly in all diabetics before and regularly during therapy with cyproterone.

Hematology: Hypochromic anemia has been observed rarely during therapy with cyproterone. Regular hematological assessment is recommended.

Nitrogen Balance: A negative nitrogen balance is usual at the start of therapy, but does generally correct itself within 3 months of continued therapy.

Metabolic Effects: Fluid retention, hypercalcemia and changes in plasma lipid profile may occur. Accordingly, cyproterone should be used with caution in patients with cardiac disease.

Skin: Cyproterone therapy may cause a reduction of sebum production leading to dryness of the skin, and transient patchy loss of body hair.

Concomitant Alcohol: Alcohol may reduce the antiandrogenic effect of cyproterone in hypersexuality. The relevance of this in prostatic carcinoma is not known, however, it would be prudent to inform the patients that the use of alcohol during cyproterone therapy is not advisable.

Patients should be informed that fatigue and lassitude are common in the first few weeks of therapy, but usually becomes much less pronounced from the third month on.

Marked lassitude and asthenia necessitate special care when driving or operating machinery.

Adverse Effects: The adverse events associated most frequently with the use of cyproterone are those related to the hormonal effects of the drug. These reactions usually disappear upon discontinuation of therapy or reduction of dose: increased libido, breast enlargement, breast tenderness, benign nodular hyperplasia of the breast, galactorrhea, gynecomastia, abnormal spermatozoa, impotence and inhibition of spermatogenesis.

Other adverse events which have been reported are listed below:

Cardiovascular: hypotension, tachycardia, heart failure, syncope, myocardial infarct, hemorrhage, cerebrovascular accident, cardiovascular disorder, retinal vascular disorder, embolus, pulmonary embolism, superficial and deep thrombophlebitis, thrombosis, retinal vein thrombosis, phlebitis, vascular headache and shock.

Gastrointestinal: constipation, diarrhea, indigestion, anorexia, nausea, vomiting, cholestatic jaundice, cirrhosis of liver, hepatic coma, hepatitis, hepatoma, hepatomegaly, jaundice, liver carcinoma, liver failure, abnormal liver function test, liver necrosis, pancreatitis and glossitis.

Hematology: increased fibrinogen, decreased prothrombin, thrombocytopenia, anemia, hemolytic anemia, hypochromic anemia, normocytic anemia, leukopenia and leukocytosis.

Metabolism: negative nitrogen balance, decreased response to ACTH, hyperglycemia, lowered cortisol, hypercalcemia, increased AST, increased ALT, increased creatinine, hypernatremia, edema, weight gain, weight loss and diabetes mellitus.

Musculoskeletal: myasthenia, osteoporosis.

Nervous System: fatigue, lassitude, weakness, hot flashes, increased sweating, aphasia, coma, depression, dizziness, encephalopathy, hemiplegia, personality disorder, psychotic depression, abnormal gait and headache.

Respiratory: asthma, increased cough, dyspnea, hyperventilation, respiratory disorder, shortness of breath on effort and lung fibrosis.

Skin: eczema, urticaria, erythema nodosum, exfoliative dermatitis, rash, maculopapular rash, dryness of the skin, pruritus, alopecia, hirsutism, skin discolouration, photosensitivity reactions and scleroderma.

Sensory System: ear disorder, optic atrophy, optic neuritis, abnormality of accommodation, abnormal vision, blindness and retinal disorder.

Urogenital: enlarged uterine fibroids, uterine hemorrhage, increased urinary frequency, bladder carcinoma, kidney failure, hematuria, urate crystalluria, urine abnormality.

Other: ascites, allergic reaction, asthenia, chills, fetal chromosome abnormality, death, fever, hernia, malaise and injection site reaction.

Adverse reactions are rarely of sufficient severity to require dosage reduction or discontinuation of treatment.

If reactions are severe, it may be beneficial to reduce the dosage.

Overdose: Symptoms and Treatment: There have been no reports of fatal overdosage in man with cyproterone. There are no specific antidotes and treatment should be symptomatic. If oral overdosage is discovered within 2 to 3 hours, gastric lavage can safely be used if indicated.

Dosage: Androcur: The usual daily initial and maintenance dose is 200 to 300 mg (4 to 6 tablets) divided into 2 to 3 doses and taken after meals.

Hi,

My dosage on androcur was 100 mg for 2 weeks, then 150 mg for 3 weeks, then for the last 2 months back down to 100mg. estrogel 5mg. motilium 60 to 80 mg depending on the amount of breast milk.

I feel calm,........ at peace with my self. don't have erections driving me crazy. I get blood test once a month, so far everything is okay

Dale

Hi again,

ps..........I forgot I also take 10mg provera for about half the month

Dale

And the suggested dosage of Androcur on the paperwork is 300 mg. per day. I just read the pamphlet myself today... None of us have taken that much to my knowledge.

I ordered Androcur on-line today and expect it next week. I want to take daily photos documenting the shrinkage of my penis and balls.

Do you think anyone would want to see my progress over time? Anyone know where I can post photos on this site or a similar one? I'm not a webpage or computer guy by any means.

Before I started my androcur treatment I measured the distance around the balls when they are at the bottom of the sack. I used a cloth tape measure. I would measure the balls at the start of the month and again on the 15th. Measuring is the only sure way you know if they are truly shrinking. Your eyes will play tricks on you.

So, Bobbie, how much did they shrink, may I ask? Did you take pictures?